Clinical Trials Directory

Trials / Completed

CompletedNCT06690502

Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination

Safety Profile of Booster IndoVac COVID-19 Vaccination in Healthy Populations Aged 18 Years and Above

Status
Completed
Phase
Study type
Observational
Enrollment
1,208 (actual)
Sponsor
PT Bio Farma · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study is Post Authorization Safety Study (PASS) Phase IV of Booster IndoVac COVID-19 Vaccination

Detailed description

This study is Post Authorization Safety Study (PASS) Phase IV, to assess any local and systemic reaction after immunization with IndoVac using retrospective cohort study trial design to assess safety profile following IndoVac booster vaccine in healthy populations aged 18 years and above.

Conditions

Timeline

Start date
2023-12-18
Primary completion
2024-06-03
Completion
2024-06-07
First posted
2024-11-15
Last updated
2024-11-15

Locations

28 sites across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT06690502. Inclusion in this directory is not an endorsement.